H3B-6527 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), which plays a significant role in certain cancers, particularly hepatocellular carcinoma (HCC). Its primary application is in cancer research and therapy, specifically targeting tumors that are driven by FGFR4 signaling. By inhibiting FGFR4, H3B-6527 can potentially reduce tumor growth and proliferation, making it a promising candidate for treating HCC and other FGFR4-dependent cancers. It is also used in preclinical studies to better understand the role of FGFR4 in cancer biology and to evaluate its efficacy as a targeted therapeutic agent.